Your browser is no longer supported. Please, upgrade your browser.
Settings
EVLO Evelo Biosciences, Inc. daily Stock Chart
EVLO [NASD]
Evelo Biosciences, Inc.
Index- P/E- EPS (ttm)-2.27 Insider Own2.68% Shs Outstand31.89M Perf Week3.42%
Market Cap260.22M Forward P/E- EPS next Y-2.29 Insider Trans- Shs Float30.04M Perf Month21.43%
Income-72.50M PEG- EPS next Q-0.63 Inst Own86.30% Short Float5.94% Perf Quarter-0.85%
Sales- P/S- EPS this Y-78.40% Inst Trans0.37% Short Ratio29.89 Perf Half Y-5.23%
Book/sh3.12 P/B2.62 EPS next Y8.00% ROA-48.10% Target Price20.25 Perf Year-39.87%
Cash/sh3.56 P/C2.29 EPS next 5Y- ROE-57.30% 52W Range4.90 - 15.89 Perf YTD-37.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.47% Beta-
Dividend %- Quick Ratio11.90 Sales past 5Y- Gross Margin- 52W Low60.70% ATR0.82
Employees75 Current Ratio11.90 Sales Q/Q- Oper. Margin- RSI (14)59.63 Volatility13.48% 11.55%
OptionableNo Debt/Eq0.15 EPS Q/Q-24.50% Profit Margin- Rel Volume4.07 Prev Close8.16
ShortableYes LT Debt/Eq0.15 EarningsAug 06 BMO Payout- Avg Volume59.75K Price7.87
Recom2.00 SMA2017.09% SMA5016.92% SMA200-8.34% Volume242,992 Change-3.55%
Apr-30-19Initiated Jefferies Buy $18
Jan-29-19Initiated Chardan Capital Markets Neutral $10
Sep-20-19 07:00AM  Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815 GlobeNewswire
Sep-17-19 07:00AM  Evelo Biosciences Announces the Appointment of David Epstein as Chairman of its Board of Directors GlobeNewswire
Sep-03-19 08:00AM  Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire
Aug-06-19 10:24PM  Evelo Biosciences, Inc. (EVLO) Q2 2019 Earnings Call Transcript Motley Fool +5.92%
07:01AM  Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial GlobeNewswire
07:00AM  Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results GlobeNewswire
Jul-30-19 08:00AM  Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, August 6th GlobeNewswire
Jul-25-19 08:00AM  Evelo Biosciences Secures $45 Million Debt Financing from K2 HealthVentures GlobeNewswire -5.46%
Jul-15-19 08:00AM  Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors GlobeNewswire
May-30-19 08:00AM  Evelo Biosciences to Present at Upcoming Investor Conferences in June GlobeNewswire
May-27-19 10:29AM  Introducing Evelo Biosciences (NASDAQ:EVLO), The Stock That Slid 53% In The Last Year Simply Wall St.
May-15-19 08:00AM  Evelo Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-08-19 02:23PM  In slow year for life science IPOs, this venture firm is making big money American City Business Journals
May-04-19 04:23PM  Evelo Biosciences, Inc. (EVLO) Q1 2019 Earnings Call Transcript Motley Fool
May-02-19 07:00AM  Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
Apr-25-19 07:30AM  Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019 GlobeNewswire
Apr-03-19 08:00AM  Evelo Biosciences to Present at 18th Annual Needham Healthcare Conference GlobeNewswire +6.45%
Mar-04-19 07:30AM  Evelo Biosciences to Present at 39th Annual Cowen & Co. Health Care Conference GlobeNewswire
Feb-14-19 07:00AM  Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights GlobeNewswire +9.73%
Feb-07-19 08:00AM  Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019 GlobeNewswire
Jan-28-19 06:00AM  Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma GlobeNewswire
Jan-04-19 06:00AM  Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications GlobeNewswire +13.58%
Dec-05-18 08:00AM  Evelo Biosciences to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-27-18 08:00AM  Evelo Enters into Clinical Trial Collaboration Agreement with Merck GlobeNewswire
Nov-26-18 08:00AM  Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis GlobeNewswire +7.21%
Nov-13-18 08:10AM  Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-07-18 08:00AM  Evelo Biosciences to Present at Upcoming Investor Conferences in November GlobeNewswire
Nov-01-18 08:00AM  Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire +5.05%
Sep-06-18 08:00AM  Evelo Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
Aug-02-18 08:00AM  Evelo Biosciences Reports Second Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Jun-25-18 08:00AM  Evelo Biosciences Added To Russell 3000®, 2000® and Microcap® Indexes GlobeNewswire -5.34%
Jun-15-18 06:28PM  [$$] Verrica Pharma Adds to Drumbeat of Biotech IPOs The Wall Street Journal
Jun-14-18 08:00AM  Evelo Biosciences to Present at the JMP Securities 2018 Life Sciences Conference GlobeNewswire -9.05%
Jun-04-18 08:53AM  Evelo Biosciences' Potential Is 'Significant,' Says Bullish Morgan Stanley Benzinga
May-31-18 08:00AM  Evelo Biosciences Reports First Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
May-11-18 05:00PM  Evelo Biosciences Announces Closing of Initial Public Offering GlobeNewswire
May-10-18 07:18AM  [$$] Evelo Biosciences Shares Rise Slightly Post-IPO The Wall Street Journal
May-08-18 07:29PM  Evelo Biosciences Announces Pricing of Initial Public Offering GlobeNewswire
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.